Scarica l'app Stockscreener
196.74
2.20%
4.2049
Precedente Chiudi:
$192.54
Aprire:
$193.45
Volume 24 ore:
933.77K
Relative Volume:
0.69
Capitalizzazione di mercato:
$28.16B
Reddito:
$2.50B
Utile/perdita netta:
$-226.32M
Rapporto P/E:
-119.88
EPS:
-1.6412
Flusso di cassa netto:
$71.51M
1 W Prestazione:
-3.64%
1M Prestazione:
-5.57%
6M Prestazione:
-9.88%
1 anno Prestazione:
+28.39%
Intervallo 1D:
$190.05
$198.11
Intervallo di 1 settimana:
$184.81
$204.08
Portata 52W:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Nome
Natera Inc
Settore
Industria
Telefono
650-249-9090
Indirizzo
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
196.62 | 27.57B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
450.02 | 164.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
166.94 | 115.98B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
546.67 | 43.05B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
334.25 | 32.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
110.64 | 31.68B | 7.07B | 1.29B | 993.00M | 4.5355 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | William Blair | Outperform |
| 2026-01-07 | Iniziato | Citigroup | Buy |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-10-27 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Ripresa | Wells Fargo | Equal Weight |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-08 | Ripresa | Craig Hallum | Buy |
| 2024-02-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-11-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Iniziato | Bernstein | Mkt Perform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Iniziato | Stephens | Overweight |
| 2022-03-08 | Iniziato | Goldman | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-09-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-09-17 | Iniziato | SVB Leerink | Outperform |
| 2020-06-10 | Ripresa | Piper Sandler | Overweight |
| 2020-05-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Iniziato | JP Morgan | Neutral |
| 2018-07-05 | Reiterato | Piper Jaffray | Overweight |
| 2017-08-07 | Reiterato | Morgan Stanley | Overweight |
| 2016-11-10 | Reiterato | The Benchmark Company | Buy |
| 2016-05-23 | Reiterato | The Benchmark Company | Buy |
| 2016-05-11 | Reiterato | The Benchmark Company | Buy |
| 2016-04-19 | Iniziato | The Benchmark Company | Buy |
| 2015-09-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2015-08-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Iniziato | Robert W. Baird | Outperform |
| 2015-07-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Iniziato | Piper Jaffray | Overweight |
| 2015-07-27 | Iniziato | Wedbush | Neutral |
Mostra tutto
Natera Inc Borsa (NTRA) Ultime notizie
Is It Time To Reassess Natera (NTRA) After The Recent Share Price Pullback - Yahoo Finance
Natera jumps after Signatera CDx wins FDA companion diagnostic approval in bladder cancer - Quiver Quantitative
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer - The Globe and Mail
Natera wins FDA approval for companion diagnostic - MedTech Dive
5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call - Yahoo Finance
What's Behind Natera CEO Steven Chapman's Recent Stock Sales? - Kavout
A Look At Natera (NTRA) Valuation After Recent Share Price Weakness - simplywall.st
Natera, Inc. (NTRA) Investor Outlook: Exploring A 39.99% Upside With Strong Buy Ratings - DirectorsTalk Interviews
Natera, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman - GuruFocus
Natera Inc stock (US6323071042): insider selling and a sharp pullback unsettle investors - AD HOC NEWS
Natera Scores Rare FDA Approval but Shares Drop - TechStock²
Natera co-founder Sheena Jonathan sells $959,450 in company stock - Investing.com
Natera (NTRA) co-founder Jonathan Sheena sells 4,650 shares under 10b5-1 plans - Stock Titan
New blood test helps tailor bladder cancer treatment, wins FDA backing - Stock Titan
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod - Fierce Pharma
Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer - Moomoo
Natera Gets FDA Approval for Bladder-Cancer Test - marketscreener.com
Signatera CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) - Business Wire
NTRA Technical Analysis | Trend, Signals & Chart Patterns | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera’s Stronghold in Cancer Recurrence Tests Prompts Wood’s Ark to Expand Stake - The Daily Upside
(NTRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
The Cancer Test That Wall Street Is Betting On - WSJ
Natera, Inc.Common Stock (NQ: NTRA - FinancialContent
Natera NTRA Q1 2026 Earnings Call Transcript - AOL.com
Natera (NTRA) Sees Recent Investment Surge from ARK Investment - GuruFocus
Cathie Wood’s ARK sells Twist Bioscience, buys Natera stock - Investing.com India
Cathie Wood’s ARK sells Twist Bioscience, buys Natera stock By Investing.com - Investing.com Australia
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report - simplywall.st
Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Moomoo
Why Natera (NTRA) Shares Are Plunging Today - Yahoo Finance
Natera price target raised to $249 from $240 at Piper Sandler - TipRanks
Why Natera (NTRA) Is Down 5.9% After Raising 2026 Guidance But Posting a Wider Q1 Loss - simplywall.st
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
NTRA Q1 Deep Dive: Robust Volume Growth and Product Expansion Shape Outlook - Yahoo Finance
Number of shareholders of Natera, Inc. – BX:NTRA - TradingView
Earnings call transcript: Natera Inc. sees mixed Q1 2026 results; stock drops By Investing.com - Investing.com Australia
NTRA Maintained by BTIG -- Price Target Lowered to $250 - GuruFocus
Earnings call transcript: Natera Inc. sees mixed Q1 2026 results; stock drops - Investing.com
Natera stock price target lowered to $250 by BTIG on valuation - Investing.com Nigeria
Assessing Natera (NTRA) Valuation After Recent Share Price Pullback And Long Term Returns - Yahoo Finance
Assessing Natera (NTRA) Valuation After Record Q1 Growth And Ongoing Profitability Concerns - simplywall.st
Natera (NTRA) Is Up 6.6% After Record Q1 Revenue But Wider LossesHas The Bull Case Changed? - Yahoo Finance
Natera Lifts 2026 Outlook As Test Volumes Climb And Japan Entry Nears - Sahm
Natera (NTRA) Q4 Profit Of US$47.3 Million Tests Longstanding Loss‑Making Narrative - Sahm
Natera Stock To $136? - Trefis
Natera Q1 2026 slides: revenue jumps 39%, guidance raised By Investing.com - Investing.com South Africa
Natera’s Earnings Call Signals Strong Growth Momentum - TipRanks
Natera Inc Azioni (NTRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Natera Inc Azioni (NTRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sheena Jonathan | CO-FOUNDER |
May 13 '26 |
Sale |
201.56 |
1,500 |
302,347 |
19,532 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
May 05 '26 |
Sale |
213.77 |
6,986 |
1,493,363 |
2,376,402 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
May 04 '26 |
Sale |
206.16 |
722 |
148,848 |
2,382,440 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
May 04 '26 |
Sale |
210.49 |
482 |
101,456 |
57,496 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
May 01 '26 |
Sale |
206.16 |
313 |
64,528 |
57,978 |
| Sheena Jonathan | CO-FOUNDER |
May 01 '26 |
Sale |
206.16 |
107 |
22,059 |
255,652 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
May 01 '26 |
Sale |
203.69 |
3,405 |
693,560 |
142,295 |
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER |
May 01 '26 |
Sale |
206.16 |
291 |
59,993 |
187,220 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
May 01 '26 |
Sale |
206.16 |
902 |
185,956 |
149,867 |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER |
May 01 '26 |
Sale |
206.16 |
330 |
68,033 |
222,694 |
0.81%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):